Copper Patent Expiration
Copper was first introduced by Gd Searle Llc
Copper Patents
Given below is the list of patents protecting Copper, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Miudella | US10918516 | Intrauterine device with controlled copper ion elution | Jan 23, 2037 | Sebela Womens Hlth |
| Miudella | US11207209 | Intrauterine device with retrieval thread | Aug 16, 2034 | Sebela Womens Hlth |
| Miudella | US10166141 | Intrauterine contraceptive device | Jun 13, 2034 | Sebela Womens Hlth |
| Miudella | US9265652 | Intrauterine contraceptive device | Apr 28, 2034 | Sebela Womens Hlth |
| Miudella | US10022264 | Intrauterine device with retrieval thread | Mar 22, 2034 | Sebela Womens Hlth |
| Miudella | US9180040 | Intrauterine Device With Retrieval Thread | Mar 22, 2034 | Sebela Womens Hlth |
| Miudella | US10398588 | Intrauterine device with retrieval thread | Feb 24, 2034 | Sebela Womens Hlth |
| Miudella | US9610191 | Intrauterine device with retrieval thread | Feb 24, 2034 | Sebela Womens Hlth |
| Miudella | US12138199 | Intrauterine device with retrieval thread | Oct 18, 2033 | Sebela Womens Hlth |
| Miudella | US9089418 | Intrauterine contraceptive device | Apr 09, 2033 | Sebela Womens Hlth |
| Miudella | US10159596 | Intrauterine contraceptive device | Aug 14, 2032 | Sebela Womens Hlth |
| Miudella | US10188546 | Intrauterine device with controlled copper ion elution | Aug 14, 2032 | Sebela Womens Hlth |
| Miudella | US11850181 | Intrauterine contraceptive device | Aug 14, 2032 | Sebela Womens Hlth |
| Miudella | US9427351 | Intrauterine contraceptive device | Aug 14, 2032 | Sebela Womens Hlth |
Copper's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Copper:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
